Profile
Sector:
HealthcareCountry:
United StatesIPO:
17 March 1980Website:
http://www.viatris.comNext earnings report:
07 November 2024Last dividends:
23 August 2024Next dividends:
N/APrice
regular market | 3 min agoAnalysts recommendations
Institutional Ownership
VTRS Latest News
Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a worldwide healthcare firm, has announced its participation in two upcoming healthcare conferences. More information about the presentations is provided below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m.
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a worldwide healthcare firm, has been recognized on Forbes' 2024 list of the World's Top Companies for Women. This honor is given in partnership with Statista, a leading provider of statistics and industry rankings.
Lexicon will get an initial payment of $25 million, along with the possibility of additional payments based on regulatory and commercial achievements.
Viatris Inc. is expanding its innovative range of treatments for cardiovascular diseases by partnering with Lexicon Pharmaceuticals for the exclusive rights to sotagliflozin in markets outside the U.S. and Europe. This medication was approved by the U.S. FDA in May 2023 to help lower the risk of cardiovascular death and hospital visits related to heart failure in adults with certain health conditions. The agreement allows Viatris to utilize its global resources and expertise to explore more uses for sotagliflozin.
PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced the pricing details for its cash tender offer, known as the "Maximum Tender Offer," made by its subsidiary Utah Acquisition Sub Inc. This offer is for up to a total of $575,003,000 of its outstanding 3.950% Senior Notes due in 2026, which must be validly submitted and not withdrawn by the Early Tender Date.
PITTSBURGH, Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) is set to announce its financial results for the third quarter of 2024 on Thursday, November 7, 2024, before the U.S. markets open.
PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced that it, along with its subsidiary Mylan Inc., is proceeding with cash tender offers for all outstanding 1.650% Senior Notes due 2025 issued by Viatris. These offers are referred to as the "Any and All Tender Offers."
PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced the pricing details for its cash tender offers, which include both Viatris and its subsidiary Mylan Inc. These offers are for all outstanding 1.650% Senior Notes due 2025 from Viatris and 2.125% Senior Notes due 2025 from Mylan.
On September 4, 2024, Viatris Inc. announced that it and its subsidiaries, Mylan Inc. and Utah Acquisition Sub Inc., have started cash tender offers to buy back certain senior notes. These include all outstanding 1.650% Senior Notes due 2025 from Viatris, all 2.125% Senior Notes due 2025 from Mylan, and up to $450 million of 3.950% Senior Notes due 2026 from Utah Acquisition. The offers are aimed at purchasing these securities collectively referred to as the "Securities."
What type of business is Viatris?
Viatris Inc. is an American global pharmaceutical company formed as a result of the merger of Mylan and Upjohn on November 16, 2020. The company's headquarters is located in Canonsburg, Pennsylvania. The company manufactures and sells various types of medications: brand names (such as Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients. They cover a wide range of therapeutic areas such as cardiovascular, infectious diseases, oncology, immunology, CNS and anesthesia, women's health, diabetes and metabolism, gastroenterology, respiratory and allergy, dermatology.
What sector is Viatris in?
Viatris is in the Healthcare sector
What industry is Viatris in?
Viatris is in the Drug Manufacturers - Specialty & Generic industry
What country is Viatris from?
Viatris is headquartered in United States
When did Viatris go public?
Viatris initial public offering (IPO) was on 17 March 1980
What is Viatris website?
https://www.viatris.com
Is Viatris in the S&P 500?
Yes, Viatris is included in the S&P 500 index
Is Viatris in the NASDAQ 100?
No, Viatris is not included in the NASDAQ 100 index
Is Viatris in the Dow Jones?
No, Viatris is not included in the Dow Jones index
When was Viatris the previous earnings report?
No data
When does Viatris earnings report?
The next expected earnings date for Viatris is 07 November 2024